淋巴瘤诊断:以更少材料获取更多信息
综述讨论在微创诊断趋势下,利用细针穿刺或针芯活检等少量材料诊断淋巴瘤的挑战,并总结循环肿瘤细胞、循环肿瘤DNA及循环外泌体在诊断、预后和治疗监测中的近期数据,认为这些进展有望在保障患者安全的同时推进转化与临床研究。
要点
- 微创取材(细针穿刺、针芯活检)增加,使组织病理评估及整合新诊断与预后检测面临挑战。
- 循环肿瘤细胞、循环肿瘤DNA及循环外泌体可提供诊断与预后信息。
- 这些循环标志物有望辅助诊断、预后判断与治疗监测。
核心结论
- 循环肿瘤细胞、循环肿瘤DNA及循环外泌体的检测进展有望在持续保障患者安全的同时,推进发现、转化和临床研究。
研究设计与样本
- 综述,检索范围未在原文中报告。
主要发现
- 微创操作如细针穿刺或针芯活检的使用增加,导致在更少材料下进行准确组织病理评估及整合新诊断和预后检测面临挑战。
- 微创诊断趋势常与研究者希望研究组织标本以更好理解疾病生物学和遗传学以推动领域发展的需求相冲突。
- 新兴领域致力于从淋巴瘤患者循环血液中的材料提取大量诊断和预后数据。
- 本文综述循环肿瘤细胞、循环肿瘤DNA以及循环外泌体的检测和效用方面的近期数据。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the modern era, clinicians and pathologists increasingly make challenging diagnoses in patients with suspected lymphoma using minimal amounts of diagnostic material. The increase in utilization of minimally invasive procedures, such as fine needle aspiration or needle core biopsies, lead to challenges in our ability to make accurate histopathological assessments of disease, including the integration of new diagnostic and prognostic testing, with smaller amounts of material. The trend towards minimally invasive diagnostics is also often in conflicting interest with researchers seeking to study tissue specimens to better understand the biology and genetics of these diseases to move the field forward. Thankfully, there are emerging fields which seek to extract large amounts of diagnostic and prognostic data out of material that is circulating in the blood of patients with lymphoma. Here we will review recent exciting data regarding the use of circulating tumour cells, circulating tumour DNA, and the detection and utility of circulating exosomes and how it can assist in diagnosis, prognosis and therapeutic monitoring. These advances hold the promise to enable continued safe patient care while also advancing discovery, translational and clinical research.
引用
- Galardy PJ, Bedekovics T, Macintyre E, et al. Lymphoma diagnostics: getting more from less. Br J Haematol. 2019. PMID: 30784044. doi:10.1111/bjh.15788
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。